UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026520
Receipt number R000030378
Scientific Title The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer
Date of disclosure of the study information 2017/03/15
Last modified on 2020/03/16 15:17:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

Acronym

The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

Scientific Title

The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

Scientific Title:Acronym

The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancer

Region

Japan


Condition

Condition

non-muscle invasive bladder cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the anti-tumor effect of enzalutamide against non-muscle invasive bladder cancer and to evaluate the safety of enzalutamide in patients with non-muscle invasive bladder cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Tumor shrinkage 4 weeks after administration

Key secondary outcomes

safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

YES

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

enzalutamide administration for four weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

pathologically diagnosed non-muscle invasive bladder cancer patients

Key exclusion criteria

history of androgen deprivation therapy

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Kojima

Organization

Tsukuba University Hospital

Division name

Urology

Zip code

305-8576

Address

2-1-1, Amakubo, Tsukuba, Ibaraki, Japan

TEL

029-853-3223

Email

tkojima@md.tsukuba.ac.jp


Public contact

Name of contact person

1st name Takashi
Middle name
Last name Kawahara

Organization

Tsukuba University Hospital

Division name

Urology

Zip code

305-8576

Address

2-1-1, Amakubo, Tsukuba, Ibaraki, Japan

TEL

029-853-3223

Homepage URL


Email

tkawahar99@gmail.com


Sponsor or person

Institute

Urology department of Tsukuba University Hospital

Institute

Department

Personal name



Funding Source

Organization

Tsukuba University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tsukuba University Hospital

Address

2-1-1, Amakubo,Tsukuba city

Tel

029-853-3914

Email

rinshokenkyu@un.tsukuba.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

筑波大学附属病院


Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2017 Year 02 Month 22 Day

Date of IRB

2017 Year 03 Month 17 Day

Anticipated trial start date

2017 Year 04 Month 01 Day

Last follow-up date

2019 Year 04 Month 30 Day

Date of closure to data entry

2020 Year 09 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 03 Month 13 Day

Last modified on

2020 Year 03 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030378


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name